Neurodegenerative Disorder Therapeutics Global Market Report 2026

Description

Neurodegenerative disorder therapeutics refer to medications or gene therapies used to treat patients with neurodegenerative diseases by therapeutically addressing underlying pathogenic pathways through neuroprotection, neurorestoration, and symptom management.

The primary drug types in neurodegenerative disorder therapeutics include N-methyl-D-aspartate receptor antagonists, selective serotonin reuptake inhibitors, dopamine inhibitors, and others. Selective serotonin reuptake inhibitors are a class of medications commonly used to treat depression and certain other mental health conditions. These therapies are indicated for disorders such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, Huntington's disease, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have impacted the neurodegenerative disorder therapeutics market by increasing costs of imported biologics, gene therapy reagents, and advanced neuroprotective drugs. Segments like monoclonal antibodies and gene therapy products are most affected, particularly in North America and Europe where reliance on imports is high. This has resulted in higher treatment costs and potential delays in therapy availability. On the positive side, tariffs have incentivized domestic manufacturing, local R&D investment, and innovation in cost-effective neurodegenerative therapeutics.

The neurodegenerative disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides neurodegenerative disorder therapeutics market statistics, including neurodegenerative disorder therapeutics industry global market size, regional shares, competitors with a neurodegenerative disorder therapeutics market share, detailed neurodegenerative disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the neurodegenerative disorder therapeutics industry. This neurodegenerative disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neurodegenerative disorder therapeutics market size has grown strongly in recent years. It will grow from $21.66 billion in 2025 to $23.65 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to rising prevalence of neurodegenerative disorders, increasing aging population, limited treatment options, growing awareness about early diagnosis, expansion of hospital and neurology care infrastructure.

The neurodegenerative disorder therapeutics market size is expected to see strong growth in the next few years. It will grow to $34.13 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to development of gene therapies, advancement in monoclonal antibody treatments, integration of ai-based diagnostics and monitoring, rising investment in clinical research and trials, expansion of personalized medicine and targeted therapeutics. Major trends in the forecast period include increasing adoption of neuroprotective and neurorestorative therapies, rising focus on symptom management and patient-centric care, growth in clinical trials for novel neurodegenerative drugs, expansion of personalized and targeted therapeutic approaches, integration of home care and remote monitoring solutions.

The growing investment in research and development for neurodegenerative disorder therapeutics is expected to drive the expansion of the neurodegenerative disorder therapeutics market in the coming years. Governments and organizations are increasing R&D investments in this area due to several factors, including the rising prevalence of neurodegenerative conditions, substantial unmet medical needs, significant economic and societal impacts, and broader global health priorities. For example, in March 2023, according to the Government of Canada, a Canada-based federal administration, the Canadian government announced an investment of $38.3 million in 2023 to support and advance research into neurodegenerative diseases. As a result, continued growth in research and development funding is expected to sustain momentum in the neurodegenerative disorder therapeutics market during the forecast period.

Major companies operating in the neurodegenerative disorder therapeutics market are concentrating on the development of innovative treatment approaches, such as prodrug formulations, to improve the bioavailability, effectiveness, and safety of therapies for Parkinson's disease. Prodrugs are pharmacologically inactive compounds that are converted into active drugs within the body, enabling more controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, launched PRODUODOPA (foslevodopa/foscarbidopa) in the European Union for individuals living with advanced Parkinson's disease. This therapy uses a soluble prodrug combination to enable continuous delivery of levodopa, with the goal of reducing motor fluctuations and enhancing patients' quality of life. The launch represents a notable advancement in the management of advanced Parkinson's disease by providing an alternative to intermittent oral dosing and supporting better treatment adherence.

In March 2024, Bristol Myers Squibb Company, a US-based biopharmaceutical company, acquired Karuna Therapeutics Inc. for an undisclosed amount. Through this acquisition, Bristol Myers Squibb seeks to strengthen its neuroscience portfolio, accelerate the development of innovative therapies for neuropsychiatric disorders, and expand its research and commercial capabilities within central nervous system treatments. Karuna Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric diseases.

Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurodegenerative disorder therapeutics market includes revenues earned by entities by correction of pathogenic mechanisms, neuroprotection, neurorestoration, and symptom control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurodegenerative Disorder Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses neurodegenerative disorder therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurodegenerative disorder therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neurodegenerative disorder therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Indication Type: Parkinson's Disease; Alzheimer's Disease; Multiple Sclerosis; Huntington Disease; Other Indication Types
2) By Drug Type: N- methyl- D- aspartate Receptor; Selective Serotonin Reuptake Inhibitor; Dopamine Inhibitors; Other Drug Types
3) By Distribution: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Subsegments:
1) By Parkinson's Disease: Dopamine Agonists; MAO-B Inhibitors; COMT Inhibitors; Anticholinergics
2) By Alzheimer's Disease: Cholinesterase Inhibitors; NMDA Receptor Antagonists; Anti-Amyloid Monoclonal Antibodies
3) By Multiple Sclerosis: Immunomodulators; Immunosuppressants; Corticosteroids
4) By Huntington's Disease: Tetrabenazine; Antipsychotic Medications
5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments; Frontotemporal Dementia Treatments; Prion Disease Treatments
Companies Mentioned: Biogen Inc.; Pfizer Inc.; Novartis International AG; Sanofi S.A.; Teva Pharmaceutical Industries Ltd.; UCB S.A.; F. Hoffmann-La Roche Ltd.; ACADIA Pharmaceuticals Inc.; H. Lundbeck A/S; Boehringer Ingelheim International GmbH; Merck Serono S.A.; Orion Corporation; Mitsubishi Tanabe Pharma America; Allergan PLC; GlaxoSmithKline PLC; AbbVie Inc.; Eli Lilly and Company; Celgene Corporation; Bayer Schering Pharma AG; AstraZeneca plc; Alector Inc.; Yumanity Therapeutics Inc.; Eisai Co. Ltd.; Bristol Myers Squibb Company; Amylyx Pharmaceuticals Inc.; Genentech Inc.; AC Immune SA; Annexon Bioscience Inc.; BioArctic Neuroscience AB; Cajal Neuroscience Inc.; Cognito Therapeutics Inc.; Grifols S.A.; New Equilibrium Biosciences Inc.; Prothena Corporation PLC; Tessera Therapeutics Inc.; Vigil Neuroscience Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH5MNDTI01_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Neurodegenerative Disorder Therapeutics Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Neurodegenerative Disorder Therapeutics Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Neurodegenerative Disorder Therapeutics Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Neurodegenerative Disorder Therapeutics Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.3 Artificial Intelligence & Autonomous Intelligence
- 4.1.4 Industry 4.0 & Intelligent Manufacturing
- 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
- 4.2.1 Increasing Adoption Of Neuroprotective And Neurorestorative Therapies
- 4.2.2 Rising Focus On Symptom Management And Patient-Centric Care
- 4.2.3 Growth In Clinical Trials For Novel Neurodegenerative Drugs
- 4.2.4 Expansion Of Personalized And Targeted Therapeutic Approaches
- 4.2.5 Integration Of Home Care And Remote Monitoring Solutions

5. Neurodegenerative Disorder Therapeutics Market Analysis Of End Use Industries

5.1 Hospitals
5.2 Neurology Clinics
5.3 Specialty Care Centers
5.4 Home Care Providers
5.5 Research & Diagnostic Laboratories

6. Neurodegenerative Disorder Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Neurodegenerative Disorder Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Neurodegenerative Disorder Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Neurodegenerative Disorder Therapeutics Market Size, Comparisons And Growth Rate Analysis
7.3. Global Neurodegenerative Disorder Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Neurodegenerative Disorder Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Neurodegenerative Disorder Therapeutics Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Neurodegenerative Disorder Therapeutics Market Segmentation

9.1. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types
9.2. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types
9.3. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
9.4. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Parkinson's Disease, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
9.5. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Alzheimer's Disease, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies
9.6. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Multiple Sclerosis, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Immunomodulators, Immunosuppressants, Corticosteroids
9.7. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Huntington's Disease, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Tetrabenazine, Antipsychotic Medications
9.8. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Other Indication Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments

10. Neurodegenerative Disorder Therapeutics Market Regional And Country Analysis

10.1. Global Neurodegenerative Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Neurodegenerative Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Neurodegenerative Disorder Therapeutics Market

11.1. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Neurodegenerative Disorder Therapeutics Market

12.1. China Neurodegenerative Disorder Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Neurodegenerative Disorder Therapeutics Market

13.1. India Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Neurodegenerative Disorder Therapeutics Market

14.1. Japan Neurodegenerative Disorder Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Neurodegenerative Disorder Therapeutics Market

15.1. Australia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Neurodegenerative Disorder Therapeutics Market

16.1. Indonesia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Neurodegenerative Disorder Therapeutics Market

17.1. South Korea Neurodegenerative Disorder Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Neurodegenerative Disorder Therapeutics Market

18.1. Taiwan Neurodegenerative Disorder Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Neurodegenerative Disorder Therapeutics Market

19.1. South East Asia Neurodegenerative Disorder Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Neurodegenerative Disorder Therapeutics Market

20.1. Western Europe Neurodegenerative Disorder Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Neurodegenerative Disorder Therapeutics Market

21.1. UK Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Neurodegenerative Disorder Therapeutics Market

22.1. Germany Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Neurodegenerative Disorder Therapeutics Market

23.1. France Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Neurodegenerative Disorder Therapeutics Market

24.1. Italy Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Neurodegenerative Disorder Therapeutics Market

25.1. Spain Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Neurodegenerative Disorder Therapeutics Market

26.1. Eastern Europe Neurodegenerative Disorder Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Neurodegenerative Disorder Therapeutics Market

27.1. Russia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Neurodegenerative Disorder Therapeutics Market

28.1. North America Neurodegenerative Disorder Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Neurodegenerative Disorder Therapeutics Market

29.1. USA Neurodegenerative Disorder Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Neurodegenerative Disorder Therapeutics Market

30.1. Canada Neurodegenerative Disorder Therapeutics Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Neurodegenerative Disorder Therapeutics Market

31.1. South America Neurodegenerative Disorder Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Neurodegenerative Disorder Therapeutics Market

32.1. Brazil Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Neurodegenerative Disorder Therapeutics Market

33.1. Middle East Neurodegenerative Disorder Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Neurodegenerative Disorder Therapeutics Market

34.1. Africa Neurodegenerative Disorder Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Segmentation By Drug Type, Segmentation By Distribution, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Neurodegenerative Disorder Therapeutics Market Regulatory and Investment Landscape

36. Neurodegenerative Disorder Therapeutics Market Competitive Landscape And Company Profiles

36.1. Neurodegenerative Disorder Therapeutics Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Neurodegenerative Disorder Therapeutics Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Neurodegenerative Disorder Therapeutics Market Company Profiles
- 36.3.1. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Neurodegenerative Disorder Therapeutics Market Other Major And Innovative Companies

UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc

38. Global Neurodegenerative Disorder Therapeutics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Neurodegenerative Disorder Therapeutics Market

40. Neurodegenerative Disorder Therapeutics Market High Potential Countries, Segments and Strategies

40.1 Neurodegenerative Disorder Therapeutics Market In 2030 - Countries Offering Most New Opportunities
40.2 Neurodegenerative Disorder Therapeutics Market In 2030 - Segments Offering Most New Opportunities
40.3 Neurodegenerative Disorder Therapeutics Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations
41.2. Currencies
41.3. Historic And Forecast Inflation Rates
41.4. Research Inquiries
41.5. The Business Research Company
41.6. Copyright And Disclaimer